Influenza Virus Affects Intestinal Microbiota and Secondary *Salmonella* Infection in the Gut through Type I Interferons

Elisa Deriu¹, Gayle M. Boxx¹, Xuesong He², Calvin Pan³, Sammy David Benavidez¹, Lujia Cen², Nora Rozengurt⁴, Wenyuan Shi², Genhong Cheng¹*

¹ Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, California, United States of America, ² School of Dentistry, University of California, Los Angeles, Los Angeles, California, United States of America, ³ Department of Human Genetics, University of California, Los Angeles, Los Angeles, California, United States of America, ⁴ Department of Pathology and Laboratory Medicine, CURE Imaging and Stem Cell Biology Core, University of California, Los Angeles, Los Angeles, California, United States of America

* GCheng@mednet.ucla.edu

Abstract

Human influenza viruses replicate almost exclusively in the respiratory tract, yet infected individuals may also develop gastrointestinal symptoms, such as vomiting and diarrhea. However, the molecular mechanisms remain incompletely defined. Using an influenza mouse model, we found that influenza pulmonary infection can significantly alter the intestinal microbiota profile through a mechanism dependent on type I interferons (IFN-Is). Notably, influenza-induced IFN-Is produced in the lungs promote the depletion of obligate anaerobic bacteria and the enrichment of Proteobacteria in the gut, leading to a "dysbiotic" microenvironment. Additionally, we provide evidence that IFN-Is induced in the lungs during influenza pulmonary infection inhibit the antimicrobial and inflammatory responses in the gut during *Salmonella*-induced colitis, further enhancing *Salmonella* intestinal colonization and systemic dissemination. Thus, our studies demonstrate a systemic role for IFN-Is in regulating the host immune response in the gut during *Salmonella*-induced colitis and in altering the intestinal microbial balance after influenza infection.

Author Summary

Influenza is a respiratory illness. Symptoms of flu include fever, headache, extreme tiredness, dry cough, sore throat, runny or stuffy nose, and muscle aches. Some people, especially children, can have additional gastrointestinal symptoms, such as nausea, vomiting, and diarrhea. In humans, there is no evidence that the influenza virus replicates in the intestine. Using an influenza mouse model, we found that influenza infection alters the intestinal microbial community through a mechanism dependent on type I interferons induced in the pulmonary tract. Furthermore, we demonstrate that influenza-induced type I interferons increase the host susceptibility to *Salmonella* intestinal colonization and
**Introduction**

Influenza is a highly contagious viral infection that has a substantial impact on global health. Notably, outbreaks of influenza infection are usually associated with an increased incidence or severity of secondary bacterial infections responsible for high levels of morbidity during seasonal influenza episodes. We and others have previously shown that IFN-Is play a critical role in the development of secondary bacterial pneumonia after influenza infection [1]. Since their discovery in 1957, IFN-Is have been recognized as the central antiviral cytokines in vertebrates [2]. The type I IFN family mainly consists of numerous subtypes of IFNα and a single IFNβ, whose induction appears to be ubiquitous in most cell types. Toll-like receptor (TLR)-mediated IFN-I induction plays a key role in facilitating antiviral responses [3]. IFN-Is bind to a common heterodimeric receptor, IFN-α/β receptor (IFNAR), composed of two subunits, IFNAR1 and IFNAR2. Binding activates the JAK/STAT pathway, which induces pro-inflammatory genes that inhibit viral replication and boost adaptive immunity [4], and regulates the transcription of multiple interferon-stimulated genes (ISGs) [5].

A recent study has shown that influenza infection can alter the composition of the intestinal flora, resulting in immunological dysregulation that may promote inflammatory gut disorders [6]. The mammalian gut harbors a complex microbiota that plays a key role in host health through its contribution to nutritional, immunological, and physiological functions. Intestinal commensals are required for maintaining gut homeostasis through dynamic interactions with the host’s immune system [7]. Resident microbiota promote gut immune homeostasis by regulating T regulatory cells (Tregs) [8] and T helper 17 cells (Th17) [9]. The gut microbiota can inhibit infection through direct microbial antagonism or by stimulating several host effectors and injury responses [10, 11]. However, the intestinal commensals also pose an enormous challenge to the host that needs to remain “ignorant” to a selection of microbial antigens and keep the bacterial load anatomically contained, while remaining responsive to its dissemination [12]. Reciprocal interactions between gut microbiota and the host immune system shape the microbial community and influence imbalances that can lead to disease [13]. These changes are often characterized by a reduction of obligate anaerobic bacteria, and a proliferation of facultative anaerobic Enterobacteriaceae [14].

Furthermore, some people with pulmonary influenza infections also experience symptoms of gastrointestinal disorders, especially children [15]. Influenza RNA is rarely recovered from their stool [15], so it is unclear whether the symptoms develop from swallowed respiratory secretions or from active infection of the gastrointestinal tract.

In order to investigate the role of IFN-Is induced during influenza infection in modulating the endogenous intestinal microbiota, we established a model of influenza pulmonary infection using genetically modified animals with defective IFNAR signaling (Ifnar1/−/− mice). Remarkably, we found that influenza infection alters the intestinal microbial community supporting gut Proteobacteria pathobionts through a mechanism dependent on IFN-Is.

While the importance of IFN-Is in antiviral defense is well established, their role during bacterial infection is more ambiguous. Moreover, we wanted to test whether primary influenza infection can predispose the host to secondary intestinal bacterial infections. We therefore developed a model of sequential influenza pulmonary infection followed by secondary Salmonella-induced colitis using Ifnar1/−/− mice to investigate the effects of IFN-Is induced during dissemination during secondary Salmonella-induced colitis through suppression of host intestinal immunity.
influenza infection on intestinal host defense against Salmonella. Interestingly, we found that lung induced IFN-Is enhanced the growth of Salmonella in the inflamed gut and increased its systemic dissemination to secondary sites. Furthermore, we found that influenza pulmonary infection resulted in a profound inhibitory effect on the intestinal antibacterial and inflammatory responses against Salmonella infection in a IFN-I dependent manner.

Results

Influenza-induced IFN-Is alter the intestinal microbiota

Previously, it was shown that influenza infection causes intestinal injury through microbiota-dependent inflammation [6]. Considering that IFN-Is are essential components of the host antiviral response, we hypothesized that these molecules might also mediate changes in the intestinal microbiota during viral influenza infection. To study this, we infected wild-type (WT) and Ifnar1 knockout (Ifnar1−/−) mice by non-surgical intratracheal instillation [16, 17] with a sublethal dose (200 infectious units) of influenza A/Puerto Rico/8/34 (PR8).

Mice were monitored daily for 17 days after infection. We assessed the microbiota composition in the fecal content of WT and Ifnar1−/− mice before PR8 or mock infection and at 9 day post infection (dpi) (Fig 1A) since the peak weight loss was observed at 9 dpi in WT and Ifnar1−/− mice. PR8 viral load was quantified after non-surgical intratracheal instillation at 1 dpi, and we detected live virus only in the lungs, neither in the colon content nor in the cecum tissue (S1A and S1B Fig). MiSeq Illumina analysis of microbial DNA extracted from fecal samples confirmed observations reported by others [18] that the mouse intestinal microbiota, independent of the genotype, consists of two major bacterial phyla, the Bacteroidetes and the Firmicutes (Fig 1B), with the most relevant classes being Bacteroidia and Clostridia (Fig 1C).

No statistical differences were found in the fecal microbiota composition between WT and Ifnar1−/− mice, either before infection at day 0 or after mock infection at day 9. Moreover, we observed low abundance of Proteobacteria in the intestinal microbiota of the uninfected and mock-infected mice, previously reported by others [19], independent of the mouse genotype (Fig 1B). Furthermore, at day 9 post PR8 infection, Bacteroidetes and Firmicutes were still the most dominant colonizers in both mouse genotypes (Fig 1B). Our findings, however, uncovered a significant blooming of Proteobacteria at day 9 after PR8 infection only in the WT mice, whereas no significant increase was noted in the Ifnar1−/− mice, irrespective of the infection (Fig 1B). Indeed, while Proteobacteria represented 1% on average in uninfected and mock-infected mice, regardless of the genotype, they comprised approximately 15% of the total fecal microbiota in the PR8-infected WT mice (p = 0.0340 One-Way ANOVA after Bonferroni correction) (Fig 1B). The most striking change in the fecal microbial community of WT mice after PR8 infection was the increased abundance of the genus Escherichia, being however mostly undetectable in uninfected and mock-infected mice of both genotypes (p = 0.0011 One-Way ANOVA after Bonferroni correction) (Fig 1C).

Overall, greater Proteobacteria colonization levels after influenza infection in WT mice were not caused by differences in Proteobacteria abundance between WT and Ifnar1−/− mice prior to PR8 infection. Moreover, the thriving of Proteobacteria after PR8 infection in the WT but not Ifnar1−/− mice supports our hypothesis that influenza virus is able to alter the intestinal microbiota, and that this action is dependent on IFN-Is. In addition, using 16S quantitative PCR (qPCR) analysis we confirmed a significant increase in Enterobacteriaceae in the stool samples of the PR8-infected WT mice, but not in the PR8-infected Ifnar1−/− mice (Fig 1D), however no significant difference was found between WT and Ifnar1−/− mice at day 0 prior to infection (Fig 1D). Furthermore, we detected a significant lower level of Segmented Filamentous Bacteria (SFB) in the stool samples of the PR8-infected WT mice compared to the uninfected
Fig 1. PR8-induced IFN-Is alter the fecal microbiota composition. Analysis of fecal microbiota in WT and Ifnar1−/− mice performed by MiSeq and 16S qPCR during influenza infection. A) Experimental model. Fecal samples were collected from mice on day 0 before infection and on day 9 after mock Influenza infection.
WT mice (S1C Fig). SFB are Clostridia-correlated bacteria closely attached to the intestinal epithelium, which are able to activate a range of host defenses, including the production of antimicrobials, development of Th17 cells and increased colonization resistance to the intestinal pathogen *Citrobacter rodentium* [9]. However, uninfected WT and *Ifnar1*-/-* mice were found similarly colonized with SFB; furthermore, the SFB abundance did not significantly change in the *Ifnar1*-/-* mice, despite PR8 infection (S1C Fig).

In summary, our findings indicate that differences in the fecal microbiota between WT and *Ifnar1*-/-* mice prior to influenza infection are insufficient to explain the PR8-mediated changes in specific endogenous bacterial population in WT mice. Similar results, as observed with influenza, were obtained when synthetic stimulators of IFN-Is such as poly I:C (pIC) [20, 21] were administered to WT and *Ifnar1*-/-* mice by non-surgical intratracheal instillation at day 0 and at day 2 (S1D Fig). Using 16S qPCR analysis we found a significant increase in *Enterobacteriaceae* at day 4 and day 5 in the fecal samples of the pIC-treated WT mice, but not in the pIC-treated *Ifnar1*-/-* mice (S1E Fig). However, lower level of SFB was found at day 4 only in pIC-treated WT mice, but not in the pIC-treated *Ifnar1*-/-* mice (S1F Fig).

Collectively, our findings highlight a critical role of type I IFN-mediated signaling induced in the lungs during pulmonary influenza infection in predisposing the host to dysbiosis. Our analysis specifically demonstrates a flourishing of resident bacteria belonging to Proteobacteria pathobionts, and a depletion of a subset of indigenous SFB.

### Influenza-induced IFN-Is impair control of *S. Typhimurium* during acute colitis

Since we demonstrated that IFNAR1-mediated signaling increased the abundance of endogenous *Enterobacteriaceae* during influenza infection, we aimed to test whether they could similarly affect the growth of *Salmonella Typhimurium* (*S. Typhimurium*), a leading cause of acute gastroenteritis and inflammatory diarrhea, using a mouse model of acute colitis. One of the hallmarks of *S. Typhimurium* virulence in mice is its systemic manifestations resembling typhoid fever; in the typhoid model no intestinal inflammation is observed, and subsequently *Salmonella* numbers in the colon content are low and extremely variable [22, 23]. To achieve colitis, *S. Typhimurium* must be administered to mice pretreated with the antibiotic streptomycin, this results in its effective colonization of the intestinal lumen, followed by high density growth and mucosal inflammation [22]. In our colitis model, WT and *Ifnar1*-/-* mice were treated with streptomycin 1 day prior to *S. Typhimurium* infection in order to achieve acute inflammation of the cecal mucosa. On day 0, mice were first infected with a sublethal dose of PR8 virus or PBS by non-surgical intratracheal instillation, then secondarily infected by oral gavage with 10⁷ CFU of *S. Typhimurium* or given LB medium alone at 5 dpi (Fig 2A). Mice were monitored daily until euthanasia at 8 dpi. At that time point, WT mice infected with PR8, followed by *S. Typhimurium*, referred to as “secondarily infected”, were noted to have significantly more weight loss than those infected only with *S. Typhimurium* (Fig 2B), and no difference in weight loss between the two groups of *Ifnar1*-/-* mice was detected at 8 dpi. The extent
Fig 2. PR8-induced IFN-Is sensitize the host to S. Typhimurium infection. A) Schematic representation of the PR8-secondary S. Typhimurium infection model. B) Body weight loss at 8 dpi of WT and Ifnar1−/− mice in secondarily infected, S. Typhimurium-only and PR8-only infected mice. **p < 0.01. C) Lung viral load was measured at 8 dpi by plaque assay in secondarily infected and PR8-only infected WT and Ifnar1−/− mice. D, E) S. Typhimurium load in the colon content at 48 h (7 dpi) and 72 h (8 dpi) after bacterial infection. F, I) 16S copy numbers of Salmonella (F) and total Enterobacteriaceae (I) per μl of microbial DNA from colon content determined at 8 dpi. **p < 0.01. G, H) S. Typhimurium load in MLN and lungs at 72 h after bacterial infection. Each dot represents one mouse, the geometric mean is indicated. N = 5 WT and 5 Ifnar1−/−; STM = 8 WT and 7 Ifnar1−/−. Abbreviations are as follows: STM, S. Typhimurium.
of the weight loss seen in secondarily infected WT mice at 8 dpi was also greater than in secondarily infected Ifnar1<sup>−/−</sup> group (Fig 2B). Lung viral load measured by plaque assay (Fig 2C) and qPCR (S2A Fig) revealed no difference between the WT and Ifnar1<sup>−/−</sup> groups, implying that the influenza infection was not the direct cause of the weight loss. However, at 7 and 8 dpi, corresponding to 48 and 72 hours (h) post S. Typhimurium infection, respectively, we found a significant increase (12-fold and 18-fold, respectively) in the S. Typhimurium burden in the colons of the WT mice previously infected with PR8 (Fig 2D and 2E). In contrast, infection with PR8 did not enhance S. Typhimurium gut colonization in the Ifnar1<sup>−/−</sup> mice (Fig 2D and 2E). Using 16S qPCR analysis, we also detected a significant increase in the Salmonella copy number in the colon content of secondarily infected WT mice at 8 dpi compared to the S. Typhimurium-only infected WT mice. No difference was detected in the Salmonella gene copies between secondarily infected Ifnar1<sup>−/−</sup> and S. Typhimurium-only infected Ifnar1<sup>−/−</sup> mice at 8 dpi (Fig 2F). These results were confirmed by 16S-Denaturing Gradient Gel Electrophoresis (DGGE) analysis performed from the microbial DNA extracted from the colon content 8 dpi (S2B Fig). Likewise, at 8 dpi, a significant increase was noted in the total Enterobacteriaceae copy number only in the colon content of secondarily infected WT mice, compared to the S. Typhimurium-only infected WT mice (Fig 2I). We interpret this rise in total Enterobacteriaceae gene copies to represent an increase in the population of Salmonella, since a rise in other Enterobacteriaceae was not detected. This is in accordance with previous observations [24] showing no overgrowth of commensal Enterobacteriaceae, despite high levels of inflammation, in mice infected with S. Typhimurium.

Finally, we enumerated S. Typhimurium in the mesenteric lymph nodes (MLN) and lungs of WT and Ifnar1<sup>−/−</sup> mice at 8 dpi. Similar to our findings regarding the colonic burden, prior infection with PR8 enhanced the ability of S. Typhimurium to disseminate to the MLN and the lungs in WT but not Ifnar1<sup>−/−</sup> mice (Fig 2G and 2H). Indeed there was significantly less dissemination of S. Typhimurium overall in the Ifnar1<sup>−/−</sup> mice compared to WT mice (Fig 2G and 2H).

Similar results in S. Typhimurium intestinal colonization were obtained when mice were infected at day 5 with 10<sup>3</sup> CFU of S. Typhimurium, without streptomycin pretreatment (typhoid model) (S2C and S2D Fig). Indeed, as expected, S. Typhimurium numbers in the colon content were low and highly variable in S. Typhimurium-only infected WT and Ifnar1<sup>−/−</sup> mice, whereas prior infection with PR8 was still able to increase S. Typhimurium gut colonization in WT, but not in Ifnar1<sup>−/−</sup> mice (S2D Fig).

Overall, these results further support our hypothesis that PR8 infection predisposes mice to secondary Salmonella infection in a IFN-I-dependent manner.

We further tested whether pIC could elicit similar effects in our acute colitis mouse model as shown with influenza. WT and Ifnar1<sup>−/−</sup> mice were intraperitoneally (i.p.) injected with pIC or saline 1 day prior and 2 days after the oral gavage administration of 10<sup>7</sup> CFU of S. Typhimurium or LB alone (S3A Fig). Alternatively, WT and Ifnar1<sup>−/−</sup> mice were treated with pIC through non-surgical intratracheal instillation 1 day prior and 1 day after the oral gavage administration of 10<sup>7</sup> CFU of S. Typhimurium (S4A Fig). S. Typhimurium CFUs were measured in the colon content, MLN, lungs and spleen at 72 h post bacterial infection. We found that pIC treatment significantly increased the S. Typhimurium burden in the luminal colon of the WT mice, but not Ifnar1<sup>−/−</sup> mice (S3B Fig and S4B Fig). Moreover, we found that pIC enhanced S. Typhimurium dissemination in the WT but not in the Ifnar1<sup>−/−</sup> group (S3C–S3E Fig and S4C–S4E Fig). These findings imply that the pro-bacterial effects induced by pIC during S. Typhimurium infection are largely mediated by IFN-Is, and that these can potently enhance S. Typhimurium pathogenicity.
In summary, our studies have consistently shown that IFN-Is confer a fitness advantage to *Salmonella* in colonizing the intestine and disseminating to systemic sites.

**Influenza-induced IFN-Is inhibit the antimicrobial response in S. Typhimurium-induced colitis**

We next investigated whether IFN-Is might augment *Salmonella* intestinal colonization and dissemination through the suppression of specific well-characterized antimicrobial genes. To this end, we analyzed the expression of the following: *Ifnγ*, the gene that is of pivotal importance in host defense against intramacrophage pathogens [25], in *Salmonella*-induced colitis [26–28] and in the systemic control of *Salmonella* infections [29, 30]; *S100A9*, the gene that encodes one of the two subunits of calprotectin, an antimicrobial heterodimer that acts as a metal-sequestering protein, which can starve *Salmonella* and many other microorganisms of critical nutrients, such as zinc and manganese [24, 31]; Lcn2, the gene that encodes the antimicrobial peptide lipocalin-2, which sequesters iron-laden siderophores to inhibit *Enterobacteriaceae* growth [32]. We and others had already noted that transcript levels of *Ifnγ*, *S100A9*, and *Lcn2* were increased in the ceca of WT streptomycin-pretreated mice during *S. Typhimurium* infection [24, 33].

We next chose to compare transcript levels in WT and *Ifnar1*−/− mice, which were both previously PR8- or mock-infected, and secondarily infected with *S. Typhimurium*, following the infection model depicted in Fig 2A. At 8 dpi, cecal tissue was excised from the large intestines of WT and *Ifnar1*−/− mice, and transcription of the candidate antimicrobial genes was measured by qPCR. Although basal transcription of *Ifnγ*, *S100A9* and *Lcn2* was similar between mock-infected WT and mock-infected *Ifnar1*−/− mice (Fig 3A, 3C and 3E), the transcription of *Ifnγ* and *Lcn2* was significantly higher in the ceca of the *Ifnar1*−/− group, compared to the WT group, after infection with *S. Typhimurium* alone (Fig 3A and 3E). Moreover, PR8 infection alone did not change the induction level of these genes in the ceca of WT and *Ifnar1*−/− mice (Fig 3A, 3C and 3E). Differences were also confirmed in WT mice at the protein level; Western Blot revealed drastically reduced production of *S100A9* and *Lcn2* in the ceca of the secondarily *S. Typhimurium*-infected mice compared to those only infected with *S. Typhimurium* alone (Fig 3A, 3C and 3E). Moreover, *Ifnar1*−/− groups showed no difference in the expression of these antimicrobial peptides when comparing the two infection groups (Fig 3D and 3H). The concentration of *Ifnγ* in the serum of either WT and *Ifnar1*−/− mice infected only with PR8 or PBS did not rise above basal levels (36 pg/ml for WT-PR8 and 66 pg/ml for *Ifnar1*−/−-PR8–infected groups; Fig 3G). Yet, the serum level of *Ifnγ* was found drastically reduced in the secondarily infected WT group, in comparison with the S. Typhimurium–infected WT group; by contrast, no disparity was detected between the same groups in the *Ifnar1*−/− cohort (Fig 3G).

Similar effects were observed when the i.p. pIC model instead of the PR8 infection was employed (S5 Fig). *S100A9* and *Lcn2* were both strongly inhibited at the transcript (S5A and S5B Fig) and protein level (S5E and S5F Fig) in the ceca of WT but not *Ifnar1*−/− mice following pIC treatment then *S. Typhimurium* infection. Cecal *Ifnγ* transcription levels were also reduced by pIC treatment in the WT mice infected with *S. Typhimurium*, but not in the *S. Typhimurium*-infected *Ifnar1*−/− mice (S5C Fig). Moreover, pIC treatment dramatically lowered the *Ifnγ*
**Fig 3.** PR8-induced IFN-Is inhibit antimicrobial activity during *S. Typhimurium* infection. WT and *Ifnar1*−/− mice were infected with PR8 or PBS on day 0, followed by intragastric (i.g.) infection with *S. Typhimurium* or LB at 5 dpi. A, C, E) *Ifnγ, S100A9* and *Lcn2* transcript levels were detected by qPCR in the mouse cecum of WT and *Ifnar1*−/− at 8 dpi. G) *Ifnγ* level was detected by ELISA in the serum of WT and *Ifnar1*−/− at 8 dpi. B, D) S100A9 and F, H) Lcn2 were detected by western blot.
detected by immunoblot in the mouse cecum of WT (B, F) and Ifnar1−/− (D, H) at 8 dpi. Each dot represents one mouse, the geometric mean is indicated. *P values were calculated by two-tailed Mann-Whitney test. **p < 0.01, ***p < 0.001; ns, not significant. Two independent experiments are shown in A, C, and E. Three independent experiments are shown in G. One representative experiment is shown in B, D, F and H. N of mice used in each group in (A, C, E, G): mock = 3–4 WT and 3 Ifnar1−/−, PRB = 3–5 WT and 3 Ifnar1−/−, PRB+STM = 7–10 WT and 7–10 Ifnar1−/−, STM = 7–12 WT and 7–12 Ifnar1−/−. N of mice used in each group in (B, D): mock = 2 WT and 2 Ifnar1−/−, PRB = 2 WT and 2 Ifnar1−/−, PRB+STM = 3 WT and 3 Ifnar1−/−, STM = 3 WT and 3 Ifnar1−/−. N of mice used in each group in (F, H): mock = 1 WT and 1 Ifnar1−/−, PRB = 2 WT and 2 Ifnar1−/−, PRB+STM = 4 WT and 4 Ifnar1−/−, STM = 3 WT and 3 Ifnar1−/−.

IFNAR1-mediated signaling can inhibit the host antimicrobial response to Salmonella infection.

Influenza-induced IFN-Is downregulate the inflammatory response in the intestine of mice infected with S. Typhimurium

To broaden our study of the effects IFN-Is have on the level of cytokine expression in an inflammatory setting such as Salmonella-induced colitis, we examined the expression of the pro-inflammatory genes Il6 and Cxcl2, and the anti-inflammatory genes Il10 and Muc2. IL-6 and CXCL2 play important roles in macrophage activation and neutrophil function and recruitment. IL-10 and MUC2 are considered essential immunoregulators in the intestinal tract. IL-10 mainly functions to dampen excessive inflammatory responses that risk damaging the host [34, 35]. MUC2 is critical for colon protection, as Muc-2 deficient mice spontaneously develop colitis [36, 37]. Their transcript level in the cecum was assessed in both WT and Ifnar1−/− mice at 8 dpi after PR8 or mock infection, and following a secondary S. Typhimurium infection. After S. Typhimurium infection, both pro-inflammatory genes were induced in the cecum of WT and Ifnar1−/− mice (Fig 4A and 4C).

Significantly higher transcription of Il6 was observed in S. Typhimurium-only infected Ifnar1−/− mice compared to S. Typhimurium-only infected WT mice (Fig 4A). Interestingly, in WT but not Ifnar1−/− mice, the secondarily infected S. Typhimurium group showed significantly lower levels of pro-inflammatory gene transcription than the S. Typhimurium-only infected group (Fig 4A and 4C). By contrast, PR8 infection enhanced cecal Il10 levels in an IFNAR1-dependent manner (Fig 4B). Basal transcript expression of Il10 was overall similar in mock-infected WT and Ifnar1−/− mice. However, we observed a lower level of induction of Il10 in S. Typhimurium-only infected Ifnar1−/− mice compared to S. Typhimurium-only infected WT mice (Fig 4B). We did not detect upregulation of Muc2 in S. Typhimurium-only infected WT or Ifnar1−/− mice, although our samples showed a high level of variability (Fig 4D). However, in WT but not Ifnar1−/− mice, PR8 infection enhanced cecal Muc2 levels. Furthermore, we observed an approximately 10-fold upregulation of Muc2 in the secondarily infected WT group compared to the S. Typhimurium-only infected WT group (Fig 4D).

To further study the contribution of IFN-Is in the modulation of the intestinal host response during Salmonella infection, we examined the transcription of Ifnb and Ifna4 in both the lungs and cecum of mice infected with PR8. We found their induction in the lungs but not in the cecum. We also examined the transcription level of Cxcl10 and Mx1, ISGs strongly induced by IFN-Is. Strikingly, we observed approximately 10-fold upregulation of Cxcl10 in the cecum of PR8-infected WT mice compared to mock-infected WT mice. In contrast, no difference was detected between Ifnar1−/− groups (Fig 4E). Moreover, in WT but not Ifnar1−/− mice secondarily-infected with S. Typhimurium, the level of induction of Cxcl10 in the cecum was approximately 4-fold higher than S. Typhimurium-only infected mice (Fig 4E). Similarly, the cecal expression of Mx1 was largely upregulated after PR8 infection in the WT mice, but not in the Ifnar1−/− mice, and as anticipated the level of induction of Mx1 tended to be lower overall in the...
Remarkably, we observed a 12-fold upregulation of \( Mx1 \) in the secondarily infected WT mice compared to the secondarily infected \( \text{Ifnar}^{1/-} \) mice (Fig 4F).
In conclusion, the dissimilar regulation of ISGs in the cecum of WT and Ifnar1⁻/⁻ mice after PR8 infection suggest that type I IFN-mediated signaling significantly contributes to the host response against S. Typhimurium infection.

Histopathology from the cecum extracted at 8 dpi illustrates that WT and Ifnar1⁻/⁻ mice develop severe inflammation 72 h after infection with S. Typhimurium, whereas no abnormalities are seen after PR8 or mock infection. However, WT mice infected with PR8 followed by S. Typhimurium infection had reduced inflammation compared to WT mice infected with S. Typhimurium alone (Fig 5A). Indeed, the mucosal integrity (assessed by cryptitis and epithelial erosions), inflammatory cell infiltration and submucosal edema were exacerbated in the S. Typhimurium-only infected WT group compared to secondarily infected WT group (Fig 5B and 5C). However, no difference in the histopathology was noted between S. Typhimurium-only infected Ifnar1⁻/⁻ group compared to secondarily infected Ifnar1⁻/⁻ group (Fig 5A, 5C and 5D). Similar differences in the cecal inflammatory score detected by histopathology were noted when pretreating WT mice with pIC before S. Typhimurium infection (S6A–S6C Fig and S7A–S7C Fig). However, pIC did not reduce the inflammatory score in the cecum of S. Typhimurium-infected Ifnar1⁻/⁻ mice (S6A, S6C and S6D Fig; S7A, S7C and S7D Fig).

To summarize, during S. Typhimurium-induced colitis, prior infection with influenza alters gut immune response promoting anti-inflammatory cytokines and reducing pro-inflammatory cytokines through an IFNAR1-dependent mechanism. The end result is a decrease, mediated by IFN-Is, of the intestinal tissue damage in mice that were first infected with influenza prior to S. Typhimurium infection.

**Discussion**

IFN-Is are primarily considered to be antiviral and immunomodulatory cytokines [38]; their effects during bacterial infection are still controversial. Although IFN-Is have been shown to protect against and limit infection with certain bacterial pathogens [39, 40], they can also impair the clearance of others [41, 42]. This suggests a complex and bacterium-specific mechanism of action.

Influenza virus is a major cause of respiratory illness in humans, with the potential to cause lung damage and sensitize the host to secondary pulmonary infections [1]. Although gastroenteritis symptoms have been reported during infection, the mechanism through which influenza virus would affect the gut is not completely clear. Our studies have shown that influenza pulmonary infection has an effect on the mouse fecal microbiota and promotes secondary infection with the intestinal pathogen, S. Typhimurium. Importantly, we have shown that these effects are dependent on IFN-Is, which are induced in the lungs during influenza pulmonary infection. These in turn can alter the gut microbial composition and suppress host immunity to a secondary Salmonella intestinal infection.

In line with a previous study [6], we found that PR8 infection and poly I:C treatment increased the relative abundance of *Enterobacteriaceae* and decreased the number of SFB in the fecal content of WT mice. However, we found that the relative abundance of these bacterial groups remained unchanged after PR8 infection or poly I:C treatment in mice deficient in IFN-I signaling, demonstrating that IFN-Is play an essential role in regulating their numbers. Based on these results and consistent with previous observations [43], we speculate that IFN-Is might regulate the populations of the major bacterial phyla within the intestinal tract. Moreover, our analysis showed that only particular members of the fecal microbiota were affected by PR8-induced IFN-Is. While anaerobes, such as Bacteroidetes and Firmicutes, make up the majority of the healthy microbiota, IFN-Is released during influenza infection promote the blooming of indigenous Proteobacteria pathobionts to the detriment of restricted anaerobic
commensals, leading to significant intestinal disbyosis. This is in accordance with previous findings that show that bacterial imbalance characterized by an enrichment of Proteobacteria is observed during intestinal inflammatory disorders in humans, including Crohn's disease [44] and enteropathy in human immunodeficiency virus (HIV)-infected subjects [45].

In addition, we show that influenza- and poly I:C-induced IFN-Is promote the intestinal overgrowth of the bacterial pathogen S. Typhimurium, which is an important component of Enterobacteriaceae and clinically associated with severe gastroenteritis and inflammatory diarrhea in humans [46].

Furthermore, we showed that Ifnar1−/− mice were more resistant to weight loss during S. Typhimurium secondary infection than WT mice, and allowed less translocation of S. Typhimurium across the intestinal wall. Not surprisingly, we also reported an increased resistance in Ifnar1−/− mice against single S. Typhimurium infection, as indicated by reduced weight loss and bacterial dissemination, as well as higher induction of specific antibacterial genes, compared to S. Typhimurium-only infected WT mice. This is in agreement with previous reports where S. Typhimurium has been shown to induce the expression of IFN-Is by macrophages [47], along with improved host survival and enhanced control of S. Typhimurium in Ifnar1−/− mice in a necroptosis-dependent mechanism [48]. While there were differences between S. Typhimurium-only infected WT and Ifnar1−/− mice, these differences were strongly exacerbated when mice were previously infected with PR8, indicating the contribution of IFN-Is produced during influenza infection to secondary S. Typhimurium infection.

Considering that the number of S. Typhimurium that disseminated systemically was greatly increased following influenza infection in WT, but not in Ifnar1−/− mice, this suggests that IFN-Is may potentially relax the intestinal barrier to allow for Salmonella systemic dissemination. In support of this, we found that the host inflammatory and antimicrobial responses against S. Typhimurium were reduced in the intestine after influenza infection in a mechanism dependent on IFNAR. Host inflammatory responses are essential to keep Salmonella localized to the gut and to limit the systemic spread of the pathogen. The immunosuppression mediated by IFN-Is would diminish local host surveillance, resulting in poor control of Salmonella in the gut and enhanced bacterial dissemination. We demonstrated that the induction of IFN-γ was decreased at the transcriptional level in the inflamed cecum and at the protein level systemically in an IFN-I-dependent manner. This is important given the key role IFN-γ plays in intestinal antibacterial immunity, host survival and resolution of Salmonella infection [49].

The host inflammatory response against Salmonella in the gut [50] includes the synthesis of antimicrobial peptides, some of which may possess a secondary function as regulatory molecules [51]. Two critical components of the mammalian nutritional immune response against S. Typhimurium are lipocalin-2 and calprotectin, which are both highly induced by this pathogen in the inflamed gut. Lipocalin-2 and calprotectin sequester essential nutrients from microorganisms and exert an antimicrobial effect against several bacteria, including intestinal commensals. Both antimicrobials were dramatically suppressed in the inflamed gut after PR8 infection in a mechanism that depended on IFNAR signaling. Paradoxically, we know that the metal deficiency induced by high levels of both antimicrobials can be evaded by Salmonella...
through expression of high-affinity metal transporters [24, 52]. However, metal starvation may still have a critical defensive role against Salmonella by forcing infected host cells in the local microenvironment to undergo apoptosis [53, 54], thereby destroying the internalized Salmonella. Furthermore, both antimicrobial peptides act as crucial paracrine chemoattractants to recruit neutrophils [55, 56], which play a major role in preventing systemic dissemination of S. Typhimurium, as suggested by clinical and experimental data [57]. Additionally, the induction in the gut of anti-inflammatory IL10 after influenza infection might, not only inhibit the bactericidal response of macrophages, but also cause infected macrophages to function as hosts for bacterial replication, as previously shown [58]. IL-10 has been shown to be important in the pathogenesis of Salmonella infection and regulation of subsequent host immune responses. IL-10 levels are elevated in susceptible strains of mice [59] suggesting that those strains producing IL-10 at high levels cannot adequately control Salmonella infection. Moreover, the relevance of the anti-inflammatory role mediated by IFN-Is in the gut during Salmonella infection was confirmed by histopathology, which underscores the concept of the double-edged sword IFN-Is represent during secondary intestinal infections. Although IFN-I-mediated effects promote Salmonella intestinal colonization and systemic dissemination, they also limit the damage triggered by exacerbated inflammation induced by Salmonella infection. Furthermore, several clinical trials could not completely define the therapeutic effects of IFN-Is in patients with ulcerative colitis, an IBD with a complex etiology that includes genetic and environmental factors leading to chronic inflammatory responses against the gut microbiota [60, 61]. This raises important questions about the potential mechanisms of action of IFN-Is in IBDs such as ulcerative colitis. Notably, IFNβ therapy markedly attenuates the course and severity of disorders such as Multiple Sclerosis (MS). Indeed, in vitro studies previously showed that IFNβ induced the release of the anti-inflammatory cytokine IL-10 from lymphocytes acquired from patients with MS [62, 63], which might indicate that IFNβ could eventually induce an anti-inflammatory response in the colonic mucosa as well.

Many investigators have reported a variety of both beneficial and detrimental immune functions for IFN-Is during bacterial infections, and this clearly expands the old misguided notion that IFN-Is serve “only” as antiviral cytokines. Specifically, we have examined the effects of IFN-Is induced by pulmonary influenza infection in intestinal bacterial homeostasis and during secondary enteric infection. We propose that during influenza infection, this family of cytokines alters the intestinal microbiota composition, leading to an overgrowth of pathobionts which puts the host at risk to develop intestinal bacterial disorders. This is particularly significant as IFN-Is are currently being used as anti-inflammatory therapies for several immunological disorders such as IBD and MS.

Furthermore, we propose that influenza-induced IFN-Is enhance susceptibility to Salmonella intestinal colonization and dissemination during secondary Salmonella-induced colitis through suppression of host intestinal immunity.

Our work highlights the critical importance of further studies that clarify the roles and effects IFN-Is play in balancing host susceptibility to bacterial infection and inflammatory control, as well as the potential risk associated with influenza infection in predisposing the host to Salmonella infections and intestinal disorders.

**Materials and Methods**

**Bacterial strain and culture conditions**

IR715 is a fully virulent, nalidixic acid-resistant derivative of Salmonella enterica serotype Typhimurium WT isolate ATCC 14028 [64]. The strain was cultured aerobically in Luria Bertani (LB) broth at 37°C. Bacterial strains and plasmids used in this study are listed in S1 Table.
Carbenicillin was added to final 100 mg/L as needed. To render all strains equally resistant to streptomycin, pH45omega plasmid [65] was introduced by electroporation.

Mouse experiments
7–9 week old mice with a C57BL/6J genetic background were used in all experiments. Ifnar1−/− mice were generated as previously reported [42]. The same number of males and females were used in each treatment group. Colonies of Ifnar1−/− and WT mice were maintained and housed in the same pathogen-free facilities at UCLA. The mouse studies described in this manuscript were performed under the written approval of the UCLA Animal Research Committee (ARC) in accordance to all federal, state, and local guidelines. All studies were carried out under strict accordance to the guidelines in The Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and the accreditation and guidelines of the Association for the Assessment and Accreditation of Laboratory Animal Care (AALAC) International under UCLA OARC Protocol Number 2009-012-21.

Viral mouse infection and lung collection
Mice were infected with a sublethal dose (200 PFU) of the mouse-adapted influenza A/Puerto Rico/8/34 (PR8) virus strain by non-surgical intratracheal instillation [66].

Briefly, mice were anesthetized with a mixture of ketamine and xylazine (100 mg/10 mg/kg), suspended by an incisor wire on an angled stand, and then a fixed volume containing 200 PFU of PR8 in pharmaceutical grade PBS was instilled inside the trachea [66]. Following aspiration of the inoculum into the lungs, mice were maintained on warming pads and monitored until completely ambulatory. Mice were monitored daily and weight was recorded. On day 1, 8 or 17 after PR8 (or mock) infection, mice were euthanized by CO2 asphyxiation. Lungs were excised, lobes were separated and placed in a 2 mL FastPrep homogenization tube containing lysing matrix D. Sterile DPBS was added to give a final 20% w/v suspension and homogenized using a FastPrep-24 Instrument, 6 m/s, 45 s (MP Biomedicals, Santa Ana, CA). Lung homogenate was diluted 1:10 in TRIzol Reagent (Life Technologies, Grand Island, NY) for analysis of gene expression, or serially diluted with DPBS for quantification of bacterial burden by CFU analysis and viral titer by plaque assay.

Viral titering
Viral titer was determined by plating a monolayer of MDCK cells in 6-well tissue culture treated plates, then incubating with lung homogenate, serially diluted in virus dilution buffer (PBS with 1% Pencillin/Streptomycin, 0.2% BSA, 0.005% DEAE Dextran, 1X CaCl2/MgCl2), for 1 h at 37°C. Extracellular virus was removed by gently washing the monolayer, then an overlay containing 2% low melting point agarose in virus growth medium (MEM containing BME vitamins, 10 mM HEPES, 1% Pencillin/Streptomycin, 0.15% NaHCO3, 0.2% BSA, 0.0015% DEAE Dextran, 0.7 mg/ml TPCK-treated Trypsin) was applied and plates were incubated for 2 days at 37°C. The overlay was gently aspirated, then the plates were incubated with 0.3% crystal violet in 20% ethanol and plaque forming units (PFU) were enumerated.

Analysis of the fecal microbiota after influenza infection
Mice were administered 200 PFU of PR8 virus or PBS through non-surgical intratracheal instillation [66].

Mice were monitored daily at the same time until day 17, when all the mice were euthanized. Fecal samples were collected from WT and Ifnar1−/− mice before PR8 or mock infection on day 0 and at 9 dpi, then snap frozen in liquid nitrogen. The fecal DNA was subsequently
extracted using the QIAamp DNA stool kit (Qiagen), according to the manufacturer’s instructions. The fecal microbial DNA was used for 16S quantitative real-time PCR (qPCR) analysis and for Illumina MiSeq analysis.

Two μl of extracted fecal bacterial DNA was used as a template for 16S qPCR reaction with the primer pairs previous developed and presented in S2 Table. The 16S gene copy numbers per μl of DNA from each sample (one fecal pellet collected from each mouse) was determined using the plasmids described in S1 Table.

For MiSeq analysis, bacterial DNA was amplified by a two-step PCR enrichment of the 16S rDNA (V4 region) encoding sequences from each sample with primers 515F and 806R modified by addition of barcodes for multiplexing. Libraries were sequenced using an Illumina MiSeq system. Following quality filtering, the sequences were demultiplexed and trimmed before performing sequence alignments, identification of operational taxonomic units (OTU), clustering, and phylogenetic analysis using QIIME open-source software (http://qiime.org).

**Secondary S. Typhimurium infection**

Mice were infected on day 0 with 200 PFU of PR8 influenza strain or PBS through non-surgical intratracheal instillation [66]. WT and Ifnar1-/− mice were orally gavaged with 0.1 ml of a 200 mg/ml streptomycin/sterile water solution on day 4, prior to mock infection in LB or oral infection with 1×10⁶ CFU of S. Typhimurium in LB on day 5. Colon content was collected at 48 h postbacterial infection, weighed, homogenized in 1 ml of sterile PBS, serial diluted and plated on LB agar containing appropriate antibiotics. At 72 h post-bacterial infection the cecum was harvested for mRNA, protein, and histopathology. The colon contents, spleen, lungs and mesenteric lymph nodes (MLN) were collected, serially diluted, and plated on appropriate antibiotic LB agar plates to determine bacterial counts. Lungs were harvested for mRNA isolation and plaque assay. Blood was collected by cardiac puncture, allowed to clot at room temperature; serum was isolated by centrifugation, transferred to a sterile tube and stored at -80°C until ELISA cytokine analysis. Groups of 4–6 mice were used for each experiment. Mouse weight was taken daily until euthanasia.

For the typhoid model, WT and Ifnar1-/− mice were infected on day 0 with 200 PFU of PR8 influenza strain or PBS through non-surgical intratracheal instillation [66]. Mice were gavaged with 1×10³ CFU of S. Typhimurium in LB, without streptomycin pre-treatment, on day 5. The colon contents were collected at 72h post bacterial infection, serially diluted, and plated on appropriate antibiotic LB agar plates to determine bacterial counts.

**Analysis of the fecal microbiota after poly I:C treatment**

Polyinosinic polycytidylic acid (#tlrl-pic) was purchased from Invivogen (San Diego, CA). Mice were administered 50 μg of pIC or saline through non-surgical intratracheal instillation [66] on day 0 and on day 2. Fecal samples were collected from WT and Ifnar1-/− mice on day 0 before treatment and on day 4 and day 5, then snap frozen in liquid nitrogen. The fecal DNA was subsequently extracted using the QIAamp DNA stool kit (Qiagen), according to the manufacturer’s instructions. The fecal microbial DNA was used for 16S qPCR analysis, as described above, and the copy numbers’ fold increase from each mock and pIC-treated sample (one fecal pellet collected from each mouse) on day 4 and day 5 over the baseline before treatment on day 0 were calculated.

**Poly I:C treatment during S. Typhimurium infection**

In the i.p. pIC model, WT and Ifnar1-/− mice were intraperitoneal injected with 150 μg of pIC or saline on day -1, and intragastrically treated with streptomycin (0.1 ml of a 200 mg/ml
solution in sterile water) [22] on day -1. Alternatively, in the non-surgical intratracheal instillation pIC model, WT and IIfnar1−/− mice were injected with 50 μg of pIC or saline on day -1, and intragastrically treated with streptomycin (0.1 ml of a 200 mg/ml solution in sterile water) [22] on day -1. In both models, mice were then orally gavaged with a dose of 10⁷ CFU of S. Typhimurium in 0.1 ml of LB on day 0 or mock-infected. A booster dose of 100 μg or 50 μg of pIC was administered on day 2 or on day 1 in the i.p pIC or in the non-surgical intratracheal instillation pIC models, respectively.

On day 3, corresponding to 72 h post S. Typhimurium infection, mice were euthanized; the cecum was collected for mRNA and protein isolation and also for histopathological analysis. Serum was separated from blood and collected for ELISA cytokine detection. CFU was enumerated from homogenates of colon content, MLN, lungs and spleen serially diluted and plated on agar plates containing the appropriate antibiotic selection.

**Quantitative real-time PCR**

Total RNA was extracted from mouse cecal tissue with TRIZol Reagent (Life Technologies). Reverse transcription of 1 μg of total RNA was performed with the iScript cDNA Synthesis kit (Bio-Rad). qPCR was performed using iTaq Universal Sybr Green Supermix (Bio-Rad). For analysis, target gene expression of each sample was normalized to the respective level of L32 mRNA. Fold changes in gene expression values were then calculated using the mean from the control samples as a baseline and determined using the ΔΔCt method. A list of qPCR primers used in this study is provided in S2 Table. See also S1 References.

**Murine cytokine ELISA**

Mouse IFNγ ELISA Ready-SET-Go! was purchased from eBioscience. Cytokine serum levels were measured according to the manufacturer’s instructions.

**Immunoblot**

Total protein was extracted from mouse cecum tissue using TRIzol Reagent (Life Technologies, Grand Island, NY). 15 μg of total protein was resolved using 12.5% SDS-PAGE gels and transferred to PVDF membranes. The membranes were blocked with 2% nonfat dried milk and incubated at 4°C with primary antibodies. Detection of mouse HSP90 α/β was performed with primary rabbit polyclonal antibodies (Santa Cruz Biotechnology), while detection of S100A9 was performed with polyclonal goat anti-mouse S100A9 (R&D Systems). Lcn-2 was detected by polyclonal goat anti-mouse Lcn2 (R&D Systems). After overnight incubation at 4°C, the blots were washed and then incubated for 1 h at room temperature with secondary goat anti-rabbit and donkey anti-goat antibodies conjugate to horseradish peroxidase (HRP) (Southern Biotech and Santa Cruz Biotechnology, respectively). After washing, bands were developed using the SuperSignal West Pico Chemiluminescent Sustrate (Thermo Scientific) per manufacturer’s instructions and visualized using Gel Doc (BioRad).

**PCR-DGGE analysis**

Total genomic bacterial DNA was isolated using the MasterPure DNA purification kit (Epicentre). DNA quality and quantity were determined with a Spectronic Genesys UV spectrophotometer at 260 nm and 280 nm (Spectronic Instruments, Inc. Rochester, NY). Amplification of bacterial 16S rDNA was carried out by PCR as described previously [67]. Briefly, the universal primer set Bac1 and Bac2 [68] (S2 Table) was used to amplify an approximately 300-base-pair internal fragment of the 16S rDNA. Each 50 μl PCR contained 100 ng purified
genomic DNA, 40 pmole each primer, 200 μM of each dNTP, 4.0 mM MgCl₂, 5 μl 10 X PCR buffer, and 2.5 U Taq DNA polymerase (Invitrogen). Cycling conditions were 94°C for 3 min, followed by 30 cycles of 94°C for 1 min, 56°C for 1 min and 72°C for 30 s, with a final extension period of 5 min at 72°C. The resulting PCR products were evaluated by electrophoresis through 1.0% agarose. DGGE was performed by use of the Bio-Rad DCode System (Hercules, CA, USA). A 40% to 60% linear DNA denaturing gradient (100% denaturant is equivalent to 7 M urea and 40% de-ionized formamide) was formed in 8% (w/v) polyacrylamide gels. Approximately 300 ng PCR product was applied per lane. The gels were submerged in 1 X TAE buffer (40 mM Tris base, 40 mM glacial acetic acid, 1 mM EDTA) and the PCR products were separated by electrophoresis for 17 h at 58°C using a fixed voltage of 60 V. After electrophoresis, the DNA bands were stained with 0.5 μg/ml ethidium bromide and DGGE profile images were digitally recorded using the Molecular Imager Gel Documentation system (Bio-Rad). DIVERSITY DATABASE Software (Bio-Rad) was used to assess the change in the relative intensity of bands corresponding to bacterial species of interest.

Identification of bacterial species from DGGE gels

The DNA bands of interest were excised from the DGGE gels and transferred to a 1.5-ml microfuge tube containing 20 μl sterile ddH₂O. Tubes were incubated at 4°C overnight before the recovered DNA samples were re-amplified with the universal primer set Bac1 and Bac2. The PCR products were purified using the QIAquick PCR purification kit (Qiagen) and sequenced at the UCLA Core DNA Sequencing Facility. The sequences obtained were submitted to nucleotide BLAST searches against the NCBI (http://blast.ncbi.nlm.nih.gov/) and Human Oral Microbiome (http://www.homd.org/index.php) databases.

Statistics

The differences between treatment groups were analyzed by non-parametric 2-tailed Mann-Whitney U test, non-parametric Kruskal-Wallis test (Dunn’s Multiple Comparison Test) and One-Way Analysis of variance (ANOVA) with Bonferroni correction, as specified in each Fig legend. Data were expressed as the geometric mean or mean ± SEM, as indicated in each Fig legend, and the results were considered statistically significant when the p value was < 0.05. All calculations were performed using GraphPad Software, unless indicated otherwise.

Histopathology

Tissue samples were fixed in formalin for 24 h, processed according to standard procedures for paraffin embedding, sectioned at 4 mm, and stained with hematoxylin and eosin. The pathology score of cecal samples was determined by blinded examinations of cecal sections by a board-certified pathologist using previously published methods [22]. Each section was evaluated for the presence of neutrophils, mononuclear infiltrate, submucosal edema, epithelial erosions and cryptitis. Inflammatory changes were scored from 0 to 4 according to the following scale: 0 = none; 1 = low; 2 = moderate; 3 = high; 4 = extreme. The inflammation score was calculated as a sum of each parameter score and interpreted as follows: 0–3 = within normal limits; 4–8 = mild; 9–14 = moderate; 15–20 = severe.

Ethics statement

The mouse studies described in this manuscript were performed under the written approval of the UCLA Animal Research Committee (ARC) in accordance to all federal, state, and local guidelines. All studies were carried out under strict accordance to the guidelines in The Guide
for the Care and Use of Laboratory Animals of the National Institutes of Health and the accreditation and guidelines of the Association for the Assessment and Accreditation of Laboratory Animal Care (AALAC) International under UCLA OARC Protocol Number 2009-012-21. Influenza infections were performed under ketamine/xylazine anesthesia and all efforts were made to minimize animal pain and discomfort.

Supporting Information

S1 Fig. Changes in the fecal microbiota after PR8 infection and poly I:C treatment are mediated by IFN-Is. A and B) WT and *Ifnar1*<sup>−/−</sup> mice (n = 4 WT, n = 4 *Ifnar1*<sup>−/−</sup>) were infected with PR8 (n = 3 WT, n = 3 *Ifnar1*<sup>−/−</sup>) or PBS (n = 1 WT, n = 1 *Ifnar1*<sup>−/−</sup>) on day 0 through non-surgical intratracheal instillation. Viral titer was determined by plaque assay in lungs and colon content on day 1 after PR8 infection (A). The levels of the influenza virus–derived matrix M protein gene in both lung and cecum tissues were quantified by qPCR on day 1 after infection (B). C) Analysis of the *Segmented Filamentous Bacteria* (*SFB*) using 16S rRNA gene qPCR from fecal samples collected from mice on day 0 before infection (n = 9 WT, n = 8 *Ifnar1*<sup>−/−</sup>), on day 9 after mock (n = 4 WT, n = 4 *Ifnar1*<sup>−/−</sup>) and PR8 infection (n = 5 WT, n = 4 *Ifnar1*<sup>−/−</sup>). Displayed are copy numbers of *SFB* per μl of fecal microbial DNA. Each dot represents one mouse, the geometric mean is indicated. D, E and F) Mice were treated with pIC (n = 4 WT, n = 3 *Ifnar1*<sup>−/−</sup>) or saline (n = 4 WT, n = 3 *Ifnar1*<sup>−/−</sup>) through non-surgical intratracheal instillation on day 0 and on day 2. Mice were euthanized on day 9. Fecal samples were collected from WT and *Ifnar1*<sup>−/−</sup> mice on day 0 before treatment and on day 4 and day 5 after treatment (D). Analysis of the fecal *Enterobacteriaceae* (E) and *SFB* (F) using 16S qPCR. Data are expressed as copy numbers’ fold increase of mock- and pIC-treated on day 4 and day 5 over the baseline before treatment on day 0. Data are expressed as mean ± SEM. P values were calculated by Kruskal-Wallis (Dunn’s multiple comparison test) in (C) and by two-tailed Mann-Whitney test in (E and F). *p value < 0.05, **p < 0.01; ns, not significant. One representative experiment is shown. Abbreviations are as follows: n.d., not detected. (TIF)

S2 Fig. Influenza-induced IFN-Is enhance host sensitivity to secondary *S. Typhimurium* infection. A) Lung PR8 was measured by qPCR at 8 dpi, and its relative expression to *L32* was calculated in WT and *Ifnar1*<sup>−/−</sup> mice that were infected with either PR8-only or secondarily infected with *S. Typhimurium*. One representative experiment is shown. N of mice used in each group in (A): PR8 = 5 WT and 2 *Ifnar1*<sup>−/−</sup>, PR8+STM = 10 WT and 4 *Ifnar1*<sup>−/−</sup>. P values were calculated in (A) using non-parametric Kruskal-Wallis test (Dunn’s multiple comparison test). B) Relative abundance of *Salmonella* in colon content of WT (left) and *Ifnar1*<sup>−/−</sup> (right) mice revealed by PCR-Denaturing Gradient Gel Electrophoresis (DGGE). Red arrows indicate the *Salmonella* band; mock: mock-infected mice on day 0; PR8: mice infected with PR8 virus on day 0; PR8+STM: mice infected with PR8 virus on day 0, followed by *S. Typhimurium* administration on day 5; STM: mice infected with *S. Typhimurium* on day 5. All the mice illustrated were streptomycin-treated by oral gavage on day 4. The luminal content used to isolate the bacterial DNA was extracted at the end of the experiment on day 8. C) Schematic representation of the secondary *S. Typhimurium* infection model in absence of streptomycin pretreatment (typhoid model). WT and *Ifnar1*<sup>−/−</sup> mice were previously infected with PR8 or PBS on day 0, then infected with 10<sup>5</sup> CFU of *S. Typhimurium* or LB alone on day 5. D) *S. Typhimurium* load in the colon content at 72 h (8 dpi) after bacterial infection in the typhoid model. P values were calculated by two-tailed Mann-Whitney test.*p < 0.05; ns, not significant. One representative experiment is shown. N of mice used in each group in (D): PR8+STM = 8 WT
S3 Fig. Poly I:C-induced IFN-Is promote S. Typhimurium intestinal colonization and systemic dissemination (i.p. model). A) Schematic of the i.p. pIC model. B, C, D, E) Colon content, MLN, lungs and spleen were harvested 72 h (day 3) post bacterial infection for enumeration of S. Typhimurium. *p value < 0.05, **p value < 0.01; ns, not significant. Data from two independent experiments are shown in (B, C, D and E). N of mice used in each group in (B): pIC + STM = 8 WT and 8 Ifnar1−/−. N of mice used in each group in (C, D, E): pIC + STM = 5–6 WT and 5 Ifnar1−/−, STM = 5–6 WT and 5 Ifnar1−/−.

(TIF)

S4 Fig. Poly I:C-induced IFN-Is promote S. Typhimurium intestinal colonization and systemic dissemination (non-surgical intratracheal instillation model). A) Schematic of the non-surgical intratracheal instillation pIC model. B, C, D, E) Colon content, MLN, lungs and spleen were harvested 72 h (day 3) post bacterial infection for enumeration of S. Typhimurium. *p value < 0.05, **p value < 0.01; ns, not significant. Data from a representative experiment is shown. N of mice used in each group in (B, C, D, E): pIC + STM = 5 WT and 5 Ifnar1−/−.

(TIF)

S5 Fig. Poly I:C-induced IFN-Is inhibit host immunity during S. Typhimurium infection. A, B, C) S100A9, Lcn2 and Ifnγ transcript levels were detected by qPCR in the i.p. pIC model from cecum of WT and Ifnar1−/− mice 72 h post infection. D) Serum Ifnγ protein was assessed by ELISA in the i.p. pIC model from cecum of WT and Ifnar1−/− mice 72 h post infection. E, F) HSP90α/β, Lcn2 and S100A9 were detected by immunoblot in the i.p. pIC model from cecum of WT (E) and Ifnar1−/− (F) mice 72 h post infection from a representative experiment. Each dot represents one mouse, the geometric mean is indicated. *p values were calculated by two-tailed Mann-Whitney test. *p value < 0.05, **p value < 0.01, ***p value < 0.001; ns, not significant. N of mice used in each group in (A, B, C, D): mock = 3 WT and 3 Ifnar1−/−, pIC = 3–5 WT and 3–5 Ifnar1−/−, pIC+STM = 7–10 WT and 7–10 Ifnar1−/−, STM = 7–10 WT and 7–10 Ifnar1−/−. N of mice used in each group in (E, F): mock = 1 WT and 1 Ifnar1−/−, pIC = 4WT and 4 Ifnar1−/−, pIC+STM = 5 WT and 5 Ifnar1−/−, STM = 3 WT and 3 Ifnar1−/−. The samples showed were pooled from two independent experiments in (A, B, C and D) or used from one representative experiment in (E, F).

(TIF)

S6 Fig. Poly I:C reduces cecal histopathology in WT mice, but not in Ifnar1−/− mice during S. Typhimurium infection (i.p. model). Blinded histopathology scores of cecal samples from WT (A, B and C) and Ifnar1−/− (A, C and, D) mice at 72 h post S. Typhimurium or mock infection, i.p. pIC- or mock- treated. The score of individual mice (circles) and the geometric mean for each group (bars) are indicated in (A). P values were calculated by two-tailed Mann-Whitney test. **p < 0.01; ns, not significant. One representative experiment is shown. N of mice used in each group in (A, C): mock = 3 WT and 3 Ifnar1−/−, pIC = 3 WT and 2 Ifnar1−/−, pIC+STM = 5 WT and 5 Ifnar1−/−, STM = 3 WT and 3 Ifnar1−/−. A detailed scoring for the animals shown in (A) is provided; each stacked column represents an individual mouse in (C). B and D) Hematoxylin and eosin (H&E)-stained sections from representative animals for each group in WT (B) and Ifnar1−/− (D) mice. Abbreviations are as follows: L, lumen; M, mucosa; SM, submucosa.

(TIF)
S7 Fig. Poly I:C reduces cecal histopathology in WT mice, but not in Ifnar1<sup>−/−</sup> mice during <i>S. Typhimurium</i> infection (non-surgical intratracheal instillation model). Blinded histopathology scores of cecal samples from WT (A, B and C) and Ifnar1<sup>−/−</sup> (A, C and D) mice at 72 h post <i>S. Typhimurium</i> or mock infection, treated or not with pIC through non-surgical intratracheal instillation. The score of individual mice (circles) and the geometric mean for each group (bars) are indicated in (A). P values were calculated by two-tailed Mann-Whitney test.

*p < 0.05; ns, not significant. One representative experiment is shown. N of mice used in each group in (A, C): mock = 2 WT and 2 Ifnar1<sup>−/−</sup>, pIC = 3 WT and 3 Ifnar1<sup>−/−</sup>, pIC+STM = 5 WT and 5 Ifnar1<sup>−/−</sup>, STM = 5 WT and 5 Ifnar1<sup>−/−</sup>. A detailed scoring for the animals shown in (A) is provided; each stacked column represents an individual mouse in (C). B and D) Hematoxylin and eosin (H&E)-stained sections from representative animals for each group in WT (B) and Ifnar1<sup>−/−</sup> (D) mice. Abbreviations are as follows: L, lumen; M, mucosa; SM, submucosa.

(TIF)

S1 Table. Strains and plasmids used in this study.

(DOCX)

S2 Table. Real-time qPCR primers used in this study.

(DOCX)

S1 References. Supplemental references cited only in the supporting information files.

(DOCX)

Acknowledgments

We would like to acknowledge Manuela Raffatellu and her lab for the gift of <i>Salmonella</i> Typhimurium strain, plasmids and precious suggestions, Natalie Quanquin for remarkable help with editing the manuscript, Maxime Chapon for helpful discussions, UCLA Genotyping and Sequencing Core for processing samples for Illumina MiSeq analysis, and CURE (Digestive Diseases Research Center), whose services were provided by the Imaging and Stem Cell Biology Core (ISCB).

Author Contributions

Conceived and designed the experiments: ED GMB GC. Performed the experiments: ED GMB XH SDB LC. Analyzed the data: ED GMB XH CP NR GC. Contributed reagents/materials/analysis tools: WS. Wrote the paper: ED.

References

1. Shahangian A, Chow EK, Tian X, Kang JR, Ghaffari A, Liu SY, et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest. 2009; 119(7):1910–20. Epub 2009/06/03. doi: 10.1172/JCI35412 PMID: 19487810; PubMed Central PMCID: PMC2701856.

2. Fensterl V, Sen GC. Interferons and viral infections. Biofactors. 2009; 35(1):14–20. Epub 2009/03/26. doi: 10.1002/biof.6 PMID: 19319841.

3. Doyle S, Vaidya S, O’Connell R, Dadgostar H, Dempsey P, Wu T, et al. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity. 2002; 17(3):251–63. Epub 2002/10/02. PMID: 12354379.

4. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science. 1996; 272(5270):1947–50. Epub 1996/06/28. PMID: 8658169.

5. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014; 32:513–45. Epub 2014/02/22. doi: 10.1146/annurev-immunol-032713-120231 PMID: 24555472; PubMed Central PMCID: PMC4313732.

6. Wang J, Li F, Wei H, Lian ZX, Sun R, Tian Z. Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell-dependent inflammation. J Exp Med. 2014; 211
1. Winter SE, Winter MG, Xavier MN, Thiennimitr P, Poon V, Keestra AM, et al. Host-derived nitrate

2. Dilantika C, Sedyaningsih ER, Kasper MR, Agtini M, Listiyaningsih E, Uyeki TM, et al. Influenza virus

3. Zheng D, Limmon GV, Yin L, Leung NH, Yu H, Chow VT, et al. A cellular pathway involved in Clara cell

4. Yin L, Xu S, Cheng J, Zheng D, Limmon GV, Leung NH, et al. Spatiotemporal quantification of cell

5. Winter SE, Thiennimitr P, Winter MG, Butler BP, Huseby DL, Crawford RW, et al. Gut inflammation pro-

6. Garrett WS, Lord GM, Punit S, Lugo-Villarino G, Mazmanian SK, Ito S, et al. Communicable ulcerative

7. Pfefferle PI, Renz H. The mucosal microbiome in shaping health and disease. F1000Prime Rep. 2014;

8. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and

9. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, et al. Induction of intestinal Th17 cells by

10. Scales BS, Huffnagle GB. The microbiome in wound repair and tissue fibrosis. J Pathol. 2013; 229(2):

11. Pfefferle PI, Renz H. The mucosal microbiome in shaping health and disease. F1000Prime Rep. 2014;

12. Round JL, Mazmanian SK. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium

13. Garrett WS, Lord GM, Punit S, Lugo-Villarino G, Mazmanian SK, Ito S, et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell. 2007; 131(1):33–45. Epub 2007/10/10. doi: 10.1016/j.cell.2007.08.017 PMID: 17923086; PubMed Central PMCID: PMC2169385.

14. Winter SE, Winter MG, Xavier MN, Thiennimitr P, Poon V, Keestra AM, et al. Host-derived nitrate boosts growth of E. coli in the inflamed gut. Science. 2013; 339(6120):708–11. Epub 2013/02/09. doi: 10.1126/science.1233467 PMID: 23393266; PubMed Central PMCID: PMC4004111.

15. Dilantika C, Sedyaningsih ER, Kasper MR, Agtini M, Listiyaningsih E, Uyeki TM, et al. Influenza virus infection among pediatric patients reporting diarrhea and influenza-like illness. BMC Infect Dis. 2010; 10(12):33–31. Epub 2012/10/09. doi: 10.1002/path.4118 PMID: 23042513; PubMed Central PMCID: PMC3631561.

16. Zheng D, Limmon GV, Yin L, Leung NH, Yu H, Chow VT, et al. A cellular pathway involved in Clara cell to alveolar type II cell differentiation after severe lung injury. PLoS One. 2013; 8(8):e71028. doi: 10.1371/journal.pone.0071028 PMID: 23940685; PubMed Central PMCID: PMCPMC3734298.

17. Yin L, Xu S, Cheng J, Zheng D, Limmon GV, Leung NH, et al. Spatiotemporal quantification of cell dynamics in the lung following influenza virus infection. J Biomed Opt. 2013; 18(4):046001. doi: 10.1117/1.JBO.18.4.046001 PMID: 23545853.

18. Winter SE, Thiennimitr P, Winter MG, Butler BP, Huseby DL, Crawford RW, et al. Gut inflammation provides a respiratory electron acceptor for Salmonella. Nature. 2010; 467(7314):426–30. Epub 2010/01/08. doi:10.1038/nature09415 PMID: 20864996; PubMed Central PMCID: PMC2946174.

19. Peterson DA, Frank DN, Pace NR, Gordon JI. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe. 2008; 3(6):417–23. Epub 2008/06/11. doi: 10.1016/j.chom.2008.05.001 PMID: 18541218; PubMed Central PMCID: PMC2872787.

20. Mattei F, Schiavoni G, Belardelli F, Tough DF. IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J Immunol. 2001; 167(3):1179–87. Epub 2001/07/24. PMID: 11466332.

21. Tian X, Xu F, Lung WY, Meyerson C, Ghaffari AA, Cheng G, et al. Poly I:C enhances susceptibility to secondary pulmonary infections by gram-negative bacteria. PLoS One. 2012; 7(9):e41879. Epub 2012/09/11. doi: 10.1371/journal.pone.0041879 PMID: 22962579; PubMed Central PMCID: PMC3433467.

22. Barthel M, Hapfelmeier S, Quintanilla-Martinez L, Kremer M, Rohde M, Hogardt M, et al. Pretreatment of mice with streptomycin provides a Salmonella enterica serovar Typhimurium colitis model that allows analysis of both pathogen and host. Infect Immun. 2003; 71(5):2839–58. Epub 2003/04/22. PMID: 12704158; PubMed Central PMCID: PMC153285.

23. Behnsen J, Jellbauer S, Wong CP, Edwards RA, George MD, Ouyang W, et al. The cytokine IL-22 promotes pathogen colonization by suppressing related commensal bacteria. Immunity. 2014; 40(2):262–73. Epub 2014/02/11. doi: 10.1016/j.immuni.2014.01.003 PMID: 24508234; PubMed Central PMCID: PMC3964146.

24. Liu JZ, Jellbauer S, Poe AJ, Ton V, Pesciaroli M, Kehl-Fie TE, et al. Zinc sequestration by the neutrophil protein calprotectin enhances Salmonella growth in the inflamed gut. Cell Host Microbe. 2012; 11(3):227–39. Epub 2012/03/20. doi: 10.1016/j.chom.2012.01.017 PMID: 22423963; PubMed Central PMCID: PMC3308348.
25. Nairz M, Frisiche G, Brunner P, Talasz H, Hantke K, Weiss G. Interferon-gamma limits the availability of iron for intramacrophage Salmonella typhimurium. Eur J Immunol. 2008; 38(7):1923–36. Epub 2008/06/27. doi: 10.1002/eji.200738056 PMID: 18581323.

26. Spees AM, Kingsbury DD, Wangdi T, Xavier MN, Tsolis RM, Baumler AJ. Neutrophils are a source of gamma interferon during acute Salmonella enterica serovar Typhimurium colitis. Infect Immun. 2014; 82(4):1692–7. Epub 2014/01/15. doi: 10.1128/IAI.01508-13 PMID: 24241037; PubMed Central PMCID: PMC3993401.

27. Harrington L, Srikanth CV, Antony R, Shi HN, Cherayil BJ. A role for natural killer cells in intestinal inflammation caused by infection with Salmonella enterica serovar Typhimurium. FEMS Immunol Med Microbiol. 2007; 51(2):372–80. doi: 10.1111/j.1574-695X.2007.00313.x PMID: 17727655; PubMed Central PMCID: PMCPMC2059580.

28. Rhee SJ, Walker WA, Cherayil BJ. Developmentally regulated intestinal expression of IFN-gamma and its target genes and the age-specific response to enteric Salmonella infection. J Immunol. 2005; 175(2):1127–36. PMID: 16002714.

29. Ramarathinam L, Shaban RA, Niesel DW, Klimpel GR. Interferon gamma (IFN-gamma) production by a commensal but not pathogenic bacteria triggers production of protective interferon-beta. Immunity. 2010; 33(6):82–9. doi: 10.1016/j.immuni.2010.08.014 PMID: 20742504; PubMed Central PMCID: PMC2981686.

30. Shan M, Gentile M, Yeiser JR, Walland AC, Bornstein VU, Chen K, et al. Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science. 2013; 342(6157):447–53. Epub 2013/09/28. doi: 10.1126/science.1237910 PMID: 24072822; PubMed Central PMCID: PMC4005805.

31. McFadden G, Hendershot LM, Hahne M, Parke JD. Interferon-gamma enhances susceptibility to Listeria monocytogenes infection. J Exp Med. 2004; 200(4):437–45. Epub 2004/08/11. doi: 10.1084/jem.20040712 PMID: 15302091; PubMed Central PMCID: PMC2219357.

32. O'Connell RM, Saha SK, Vaidya SA, Bruhn KW, Miranda GA, Zarnegar B, et al. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J Exp Med. 2004; 200(4):437–45. Epub 2004/08/11. doi: 10.1084/jem.20040712 PMID: 15302091; PubMed Central PMCID: PMC2219357.

33. Ishihara T, Aga M, Hino K, Ushio C, Taniguchi M, Iwaki K, et al. Inhibition of chlamydia trachomatis growth by human interferon-alpha: mechanisms and synergistic effect with interferon-gamma and tumor necrosis factor-alpha. J Virol. 1992; 66(4):389–96. Epub 1992/04/01. PMID: 13774499.

34. Deriu E, Liu JZ, Pezeshki M, Edwards RA, Ochoa RJ, Contreras H, et al. Probiotic bacteria reduce salicylates and oral tolerance by delivering immunoregulatory signals. Science. 2013; 342(6157):447–53. Epub 2013/09/28. doi: 10.1126/science.1237910 PMID: 24072822; PubMed Central PMCID: PMC4005805.

35. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993; 75(2):263–74. Epub 1993/10/22. PMID: 8092191.

36. PMID:16002714.

37. Epub 2013/07/23. doi:10.1016/j.chom.2013.06.007 PMID: 23870311; PubMed Central PMCID: PMC3752295.

38. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology. 2006; 131(1):117–29. Epub 2006/07/13. doi: 10.1053/j.gastro.2006.04.020 PMID: 16831586.

39. Shan M, Gentile M, Yeiser JR, Walland AC, Bornstein VU, Chen K, et al. Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science. 2013; 342(6157):447–53. Epub 2013/09/28. doi: 10.1126/science.1237910 PMID: 24072822; PubMed Central PMCID: PMC4005805.

40. McFadden G, Hendershot LM, Hahne M, Parke JD. Interferon-gamma enhances susceptibility to Listeria monocytogenes infection. J Exp Med. 2004; 200(4):437–45. Epub 2004/08/11. doi: 10.1084/jem.20040712 PMID: 15302091; PubMed Central PMCID: PMC2219357.

41. Kawashima T, Kosaka A, Yan H, Guo Z, Uchiyama R, Fukui R, et al. Double-stranded RNA of intestinal commensal but not pathogenic bacteria triggers production of protective interferon-beta. Immunity. 2013; 38(6):1187–97. Epub 2013/06/25. doi: 10.1016/j.immuni.2013.02.024 PMID: 23791646.
44. Frank DN, St Amand AL, Feldman RA, Boedecker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A. 2007; 104(34):13780–5. Epub 2007/08/19. doi: 10.1073/pnas.0706625104 PMID: 17999761; PubMed Central PMCID: PMC1959459.

45. Vujkovic-Cvijin I, Dunham RM, Iwai S, Maher MC, Albright RG, Broadhurst MJ, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and cryptophasic cataplasia. Sci Transl Med. 2013; 5(193):193ra91. Epub 2013/07/12. doi: 10.1126/scitranslmed.3006438 PMID: 23843452; PubMed Central PMCID: PMC4094294.

46. Hohmann EL. Nontyphoidal salmonellosis. Clin Infect Dis. 2001; 32(2):263–9. doi: 10.1086/318457 PMID: 11170916.

47. Sing A, Merlin T, Knopf HP, Nielsen PJ, Loppnow H, Galanos C, et al. Bacterial induction of beta interferons in macrophages during infection with Salmonella enterica serovar Typhimurium. Nat Immunol. 2012; 13(10):954–62. Epub 2012/08/28. doi: 10.1038/ni.2397 PMID: 22922364; PubMed Central PMCID: PMC4005791.

48. Robinson N, McComb S, Mulligan R, Dudani R, Krishnan L, Sad S. Type I interferon induces necroptosis in macrophages. Cell. 2012; 148(4):820–32. Epub 2012/04/25. doi: 10.1016/j.cell.2012.03.011 PMID: 22482811; PubMed Central PMCID: PMC2118116.

49. Gordon MA, Jack DL, Dockrell DH, Lee ME, Read RC. Gamma interferon enhances internalization and early nonoxidative killing of Salmonella enterica serovar Typhimurium by human macrophages and modifies cytokine responses. Infect Immun. 2005; 73(6):3445–52. Epub 2005/05/24. doi: 10.1128/IAI.73.6.3445–3452.2005 PMID: 15903573; PubMed Central PMCID: PMC1111838.

50. Broz P, Ohlson MB, Monack DM. Innate immune response to Salmonella typhimurium, a model enteric pathogen. Gut Microbes. 2012; 3(2):62–70. doi: 10.4161/gmic.19141 PMID: 22198618; PubMed Central PMCID: PMCPMC3370950.

51. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, et al. Interleukin (IL)-51.

52. Gordon MA, Jack DL, Dockrell DH, Lee ME, Read RC. Gamma interferon enhances internalization and early nonoxidative killing of Salmonella enterica serovar Typhimurium by human macrophages and modifies cytokine responses. Infect Immun. 2005; 73(6):3445–52. Epub 2005/05/24. doi: 10.1128/IAI.73.6.3445–3452.2005 PMID: 15903573; PubMed Central PMCID: PMC1111838.

53. Devireddy LR, Teodoro JG, Richard FA, Green MR. Induction of apoptosis by a secreted lipocalin that confers an advantage to Salmonella enterica serotype Typhimurium for growth and survival in the inflamed intestine. Cell Host Microbe. 2009; 5(5):476–86. Epub 2009/05/21. doi: 10.1016/j.chom.2009.03.011 PMID: 19454351; PubMed Central PMCID: PMC2768556.

54. Li C, Chen H, Ding F, Zhang Y, Luo A, Wang M, et al. A novel p53 target gene, S100A9, induces p53-dependent cellular apoptosis and mediates the p53 apoptosis pathway. Biochem J. 2009; 422(2):363–72. Epub 2009/06/19. doi: 10.1042/BJ20081308 PMID: 19898211; PubMed Central PMCID: PMC2118116.

55. Santos RL, Raffatellu M, Bevins CL, Adams LG, Tukel C, Tsolis RM, et al. Life in the inflamed intestine, Salmonella style. Trends Microbiol. 2009; 17(11):498–506. Epub 2009/10/06. doi: 10.1016/j.tim.2009.08.008 PMID: 19819699; PubMed Central PMCID: PMC3235402.

56. Santos RL, Raffatellu M, Bevins CL, Adams LG, Tukel C, Tsolis RM, et al. Life in the inflamed intestine, Salmonella style. Trends Microbiol. 2009; 17(11):498–506. Epub 2009/10/06. doi: 10.1016/j.tim.2009.08.008 PMID: 19819699; PubMed Central PMCID: PMC3235402.

57. Santos RL, Raffatellu M, Bevins CL, Adams LG, Tukel C, Tsolis RM, et al. Life in the inflamed intestine, Salmonella style. Trends Microbiol. 2009; 17(11):498–506. Epub 2009/10/06. doi: 10.1016/j.tim.2009.08.008 PMID: 19819699; PubMed Central PMCID: PMC3235402.

58. Lee KS, Jeong ES, Heo SH, Seo JH, Jeong DG, Choi YK. IL-10 suppresses bactericidal response of neutrophil against Salmonella Typhimurium. J Microbiol. 2011; 49(6):1050–9. Epub 2011/03/29. doi: 10.4161/gmic.19141 PMID: 22965758.

59. Schroll A, Eller K, Feistritzer C, Nairz M, Sonnweber T, Moser PA, et al. Lipocalin-2 ameliorates granulocyte functionality. Eur J Immunol. 2012; 42(12):3346–57. Epub 2012/09/12. doi: 10.1002/eji.201142351 PMID: 22965758.

60. Simard JC, Girard D, Tessier PA. Induction of neutrophil degranulation by S100A9 via a MAPK-dependent mechanism. J Leukoc Biol. 2010; 87(5):905–10. Epub 2010/04/27. doi: 10.1002/jlb.0909676 PMID: 2013766.

61. Santos RL, Raffatellu M, Bevins CL, Adams LG, Tukel C, Tsolis RM, et al. Life in the inflamed intestine, Salmonella style. Trends Microbiol. 2009; 17(11):498–506. Epub 2009/10/06. doi: 10.1016/j.tim.2009.08.008 PMID: 19819699; PubMed Central PMCID: PMC3235402.

62. Lee KS, Jeong ES, Heo SH, Seo JH, Jeong DG, Choi YK. IL-10 suppresses bactericidal response of macrophages against Salmonella Typhimurium. J Microbiol. 2011; 49(6):1050–3. Epub 2011/12/29. doi: 10.4103/0973-282X.90143 PMID: 22203573.

63. Pie S, Matsiota-Bernard P, Truffa-Bachi P, Nauciel C. Gamma interferon and interleukin-10 gene expression in innately susceptible and resistant mice during the early phase of Salmonella typhimurium infection. Infect Immun. 1996; 64(3):849–54. PMID: 8641791; PubMed Central PMCID: PMCPMC173847.

64. Nikolaus S, Rutgeerts P, Fedorak R, Steinhardt AH, Wild GE, Theuer D, et al. Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut. 2003; 52(9):1286–90. Epub 2003/08/13. PMID: 12912859; PubMed Central PMCID: PMC1773804.

65. Musch E, Andrus T, Malek M, Chrissafidou A, Schulz M. Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta—an open long-term trial. Z Gastroenterol. 2007; 45(12):1235–40. Epub 2007/12/15. doi: 10.1055/s-2007-963378 PMID: 18080224.
62. Rudick RA, Ransohoff RM, Peppler R, VanderBrug Medendorp S, Lehmann P, Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol. 1996; 40(4):618–27. Epub 1996/10/01. doi: 10.1002/ana.410400412 PMID: 8871582.

63. Billiau A. Anti-inflammatory properties of Type I interferons. Antiviral Res. 2006; 71(2–3):108–16. Epub 2006/04/22. doi: 10.1016/j.antiviral.2006.03.006 PMID: 16626815.

64. Stojilkovic I, Baumler AJ, Heffron F. Ethanolamine utilization in Salmonella typhimurium: nucleotide sequence, protein expression, and mutational analysis of the cchA cchB eutE eutJ eutG eutH gene cluster. J Bacteriol. 1995; 177(5):1357–66. Epub 1995/03/01. PMID: 7868611; PubMed Central PMCID: PMC176743.

65. Prentki P, Krisch HM. In vitro insertional mutagenesis with a selectable DNA fragment. Gene. 1984; 29(3):303–13. Epub 1984/09/01. PMID: 6237955.

66. Rayamajhi M, Redente EF, Condon TV, Gonzalez-Juarrero M, Riches DW, Lenz LL. Non-surgical intratracheal instillation of mice with analysis of lungs and lung draining lymph nodes by flow cytometry. J Vis Exp. 2011;(51: ). doi: 10.3791/2702 PMID: 21587154; PubMed Central PMCID: PMCPMC3280633.

67. Li Y, Ku CY, Xu J, Saxena D, Caufield PW. Survey of oral microbial diversity using PCR-based denaturing gradient gel electrophoresis. J Dent Res. 2005; 84(6):559–64. Epub 2005/05/26. PMID: 15914595.

68. Sheffield VC, Cox DR, Lerman LS, Myers RM. Attachment of a 40-base-pair G + C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base changes. Proc Natl Acad Sci U S A. 1989; 86(1):232–6. Epub 1989/01/01. PMID: 2643100; PubMed Central PMCID: PMC286438.